Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 23, Number 1—January 2017

CME ACTIVITY - Research

Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010

Xizhong Cui1, Leisha D. Nolen1, Junfeng Sun, Malcolm Booth, Lindsay Donaldson, Conrad P. Quinn, Anne E. Boyer, Katherine Hendricks, Sean Shadomy, Pieter Bothma, Owen Judd, Paul McConnell, William A. Bower, and Peter Q. EichackerComments to Author 
Author affiliations: National Institutes of Health, Bethesda, Maryland, USA (X. Cui, J. Sun, P.Q. Eichacker); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (L.D. Nolen, C.P. Quinn, A.E. Boyer, K. Hendricks, S. Shadomy, W.A. Bower); Glasgow Royal Infirmary, Glasgow, UK (M. Booth, L. Donaldson); James Paget University Hospital, Norfolk, UK (P. Bothma); Royal Derby Hospital, Derby, UK (O. Judd); Crosshouse Hospital, Kilmarnock, UK (P. McConnell)

Main Article

Table 2

Medical history of AIG-IV recipients and nonrecipients, Scotland, UK, 2009–2010*

Variable AIG-IV nonrecipient AIG-IV recipient p value
Presentation and clinical history
Days from exposure to symptom onset, median (IQR) 1 (0.0–4.0), n = 18 2 (1.0–4.5), n = 12 0.19
Days from symptom onset to hospitalization, median (IQR) 2 (1.0–3.0), n = 25 2.0 (1.0–5.0), n = 14 0.55
Age, y, mean ± SE 34.2 ± 1.5, n = 28 37.5 ± 1.6, n = 15 0.18
Male sex 60.7 (17/28) 73.3 (11/15) 0.41
Smoker 94.4 (17/18) 81.8 (9/11) 0.54
Alcohol user 33.3 (5/15) 58.3 (7/12) 0.19
Hepatitis C infection
60 (9/15)
77.8 (7/9)
0.66
Drug injection route and site
Intravenous 50 (14/18) 40 (6/15) 0.53
Intramuscular 21.4 (6/28) 46.7 (7/15) 0.16
Arm 39.3 (11/28) 26.7 (4/15) 0.41
Groin 25 (7/28) 26.7 (4/15) 1.00
Buttock 7.1 (2/28) 26.7 (4/15) 0.16
Leg
10.7(3/28)
6.7 (1/15)
1.00
Presenting complaints
Local† 67.9 (19/28) 53.3 (8/15) 0.54
General‡ 17.9 (5/28) 20.0 (3/15)
Both% 14.3 (4/28) 26.7 (4/15)

*Values are % patients (no. patients with the finding/no. patients for whom data were available) except as indicated. n values indicate number of patients for whom data were available. AIG-IV, anthrax immune globulin intravenous; IQR, interquartile range.
†Skin lesion, limb swelling, or limb pain.
‡Fever, diaphoresis, confusion, seizures, lethargy, or malaise.

Main Article

1These authors contributed equally to this article.

TOP